These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18688879)

  • 1. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.
    Tong MJ; Hsien C; Hsu L; Sun HE; Blatt LM
    Hepatology; 2008 Oct; 48(4):1070-8. PubMed ID: 18688879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update.
    Tong MJ; Hsu L; Chang PW; Blatt LM
    J Gastroenterol Hepatol; 2011 May; 26(5):829-35. PubMed ID: 21214888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proposed, evidence-based approach to the treatment of chronic Hepatitis B.
    Han SH; Durazo FA; Saab S; Tong MJ
    J Clin Gastroenterol; 2011 Mar; 45(3):259-66. PubMed ID: 20856136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.
    Huo TI; Wu JC; Lee PC; Chau GY; Lui WY; Tsay SH; Ting LT; Chang FY; Lee SD
    Hepatology; 1998 Jul; 28(1):231-6. PubMed ID: 9657117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype C Chinese patients.
    Zheng JX; Zeng Z; Zheng YY; Yin SJ; Zhang DY; Yu YY; Wang F
    J Viral Hepat; 2011 Oct; 18(10):e423-31. PubMed ID: 21914059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
    van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
    Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
    Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
    Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
    Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
    Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
    Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
    Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers.
    Tong MJ; Blatt LM; Kao JH; Cheng JT; Corey WG
    Liver Int; 2007 Dec; 27(10):1356-63. PubMed ID: 17900245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values.
    Kumada T; Toyoda H; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Arakawa T; Fujimori M
    J Med Virol; 2010 Apr; 82(4):539-45. PubMed ID: 20166172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.